CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ — In conjunction with
DURECT Corporation’s (Nasdaq: DRRX) first quarter 2005 financial results press
release, you are invited to listen to its conference call that will be
broadcast live over the Internet on Tuesday, May 3, 2005 at 4:30 p.m. EDT.
What: DURECT Corporation’s First Quarter 2005 Earnings Conference Call
When: Tuesday May 3rd, 2005, 4:30 p.m. EDT (1:30 p.m. PDT)
Where: www.www.durect.com and click ‘Investor Relations’
Live over the Internet — Simply log on to the Web at the address
listed above.
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
section.
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic debilitating diseases and
enable biotechnology products. These platform technologies include the
SABER(TM) Delivery System (a patented and versatile depot injectable useful
for protein and small molecule delivery), the ORADUR(TM) sustained release
oral gel-cap technology (an oral sustained release technology with several
potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant
(drug-loaded implant system), the TRANSDUR(TM) transdermal technology and the
MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system).
DURECT also collaborates with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has five disclosed on-going development programs of which
four are in collaboration with pharmaceutical partners. Additional information
about DURECT is available at www.www.durect.com.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM), TRANSDUR(TM) and MICRODUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners.
SOURCE DURECT Corporation
04/19/2005
CONTACT: Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, 408-777-1417